©The Author(s) 2025.
World J Clin Oncol. Dec 24, 2025; 16(12): 112443
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112443
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112443
Figure 4 Overall survival by neoadjuvant chemotherapy in patients with peritoneal metastases.
A: In synchronous peritoneal metastases (PM), median overall survival (OS) was longer with neoadjuvant treatment (28.0 months vs 16.0 months), though not statistically significant; B: In metachronous PM, OS was similar regardless of neoadjuvant therapy. PM: Peritoneal metastases; OS: Overall survival; CHT: Chemotherapy.
- Citation: Framarini M, D'Acapito F, Lippolis PV, Di Giorgio A, Di Pietrantonio D, Sommariva A, Sammartino P. Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies. World J Clin Oncol 2025; 16(12): 112443
- URL: https://www.wjgnet.com/2218-4333/full/v16/i12/112443.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i12.112443